Pharmaceutical Resources, Inc.
Executive Summary
Distribution agreement with The Generics Group B.V. is expanded to include five additional generic drugs. ANDAs for the five unnamed drugs were submitted by divisions of The Generics Group: the Canadian firm Genpharm and the Australian firm Ameripharm. Patents for three of the five drugs have not yet expired. PRI already is the exclusive U.S. distributor of Genpharm's piroxicam and pindolol. All the products will be marketed under the name of PRI's subsidiary Par or under private label names. Par has not received an ANDA approval since 1989, but PRI expects to be cleared soon under FDA's application integrity policy.